GlassScriptPhysician profile
Raetta B Fountain
NPI 1487643854
$12,677.70
in general payments reported to CMS, 2019-2025
45 companies · $2,478 in 2025
The $2,478 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $649 · 2021: $1,724 · 2022: $2,422 · 2023: $2,497 · 2024: $2,190 · 2025: $2,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,140 · Education: $24.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,140.19 |
| Education | $24.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,150.44 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,482.22 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $703.65 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $654.36 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $497.50 | 2019-2025 | |
| Gilead Sciences, INC. | $455.47 | 2020-2025 | |
| Qol Medical, LLC | $449.76 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $410.88 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $381.99 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $362.79 | 2022-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $340.65 | 2024-2025 | Zenpep, Vowst |
| Intercept Pharmaceuticals, INC. | $308.63 | 2020-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $290.54 | 2020-2024 | Linzess |
| Genzyme Corporation | $276.96 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $276.12 | 2019-2024 | Dificid, Zinplava |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $271.75 | 2021-2025 | Qsymia, Pancreaze |
| Madrigal Pharmaceuticals | $225.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $212.53 | 2022-2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $203.67 | 2020-2023 | Rebyota, Cimzia |
| Novo Nordisk INC | $188.10 | 2025 | Wegovy |
| Lilly USA, LLC | $156.93 | 2024-2025 | Omvoh |
| Fresenius Kabi USA, LLC | $140.63 | 2023-2024 | Idacio |
| Amgen INC. | $132.30 | 2020-2023 | Amjevita, Avsola |
| Phathom Pharmaceuticals, INC. | $112.46 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $108.71 | 2020-2021 | |
| Daiichi Sankyo INC. | $107.60 | 2019-2022 | |
| Celltrion USA INC. | $106.04 | 2024-2025 | Vegzelma, Zymfentra |
| Redhill Biopharma INC. | $97.14 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $72.50 | 2024-2025 | Iqirvo, Bylvay |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.00 | 2023-2024 | Cyltezo |
| Intra-Sana Laboratories | $55.22 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.57 | 2022-2023 | |
| Braintree Laboratories, INC. | $53.71 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $47.48 | 2021-2022 | |
| Alcresta Therapeutics, INC. | $39.12 | 2024 | Relizorb |
| Biocryst US Sales Co., LLC | $25.70 | 2022 | |
| Ucb, INC. | $24.98 | 2019 | |
| Organon LLC | $24.59 | 2022 | |
| Pharmacosmos Therapeutics INC. | $24.26 | 2023 | Monoferric |
| Alfasigma USA, INC. | $17.78 | 2020 | |
| Endo Pharmaceuticals INC. | $17.69 | 2019 | |
| Romark Laboratories, Lc | $16.30 | 2019 | |
| Exact Sciences Corporation | $15.95 | 2023 | Cologuard Collection Kit |
| Biocon Biologics INC | $15.02 | 2025 | Yesintek |
| Allergan, INC. | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raetta Fountain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.